Ardent Health (ARDT) analyst forecast and price target
Analyst forecast
Consensus of 12 analyst ratings
Based on 3 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| RBC Capital | Maintained | Outperform | $13.00 from $12.00 | Aug 10, 2026 |
| Guggenheim | Maintained | Buy | $14.00 from $13.00 | Aug 6, 2026 |
| Truist Securities | Maintained | Buy | $13.00 from $12.00 | Aug 6, 2026 |
| Truist Securities | Maintained | Buy | $12.00 from $13.00 | Jul 14, 2026 |
| RBC Capital | Maintained | Outperform | $12.00 from $13.00 | Jul 9, 2026 |
| UBS | Maintained | Buy | $13.50 from $13.00 | May 7, 2026 |
| RBC Capital | Maintained | Outperform | $13.00 from $14.00 | Mar 10, 2026 |
| Leerink Partners | Maintained | Outperform | $15.00 from $16.00 | Mar 6, 2026 |
| JP Morgan | Maintained | Neutral | $11.00 from $12.00 | Jan 20, 2026 |
| Mizuho | Maintained | Outperform | $12.00 from $20.00 | Dec 18, 2025 |
| UBS | Maintained | Buy | $14.00 from $14.50 | Dec 18, 2025 |
| JP Morgan | Maintained | Neutral | $12.00 from $15.00 | Nov 24, 2025 |
| Guggenheim | Maintained | Buy | $15.00 from $18.00 | Nov 18, 2025 |
| Mizuho | Maintained | Outperform | $13.00 from $20.00 | Nov 18, 2025 |
| Keybanc | Downgraded | Overweight → Sector Weight | — | Nov 17, 2025 |
| Morgan Stanley | Downgraded | Overweight → Equal-Weight | $12.00 from $22.00 | Nov 14, 2025 |
| Stephens & Co. | Maintained | Overweight | $17.00 from $21.00 | Nov 14, 2025 |
| Truist Securities | Maintained | Buy | $13.00 from $21.00 | Nov 14, 2025 |
| RBC Capital | Maintained | Outperform | $16.00 from $21.00 | Nov 14, 2025 |
| B of A Securities | Maintained | Underperform | $10.00 from $12.00 | Nov 13, 2025 |
Frequently asked questions
What is the price target for ARDT stock?
The average 12-month analyst price target for Ardent Health (ARDT) is $13.33, with a high estimate of $14.00 and a low of $13.00, across 3 analysts.
Is ARDT a buy, sell, or hold?
Analysts covering Ardent Health currently average a Buy rating: 7 buy, 4 hold and 1 sell, from 12 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for ARDT?
The average price target of $13.33 implies 23.23% upside from the last price of $10.82.
What is the latest analyst rating on ARDT?
On Aug 10, 2026, RBC Capital maintained Ardent Health at Outperform with a price target of $13.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.